

Supplementary Table 1: Definition of medical conditions (highly) predisposing to severe Covid-19.

Medical condition	Classification	Codes	Register
Highly predisposing to severe Covid-19			
Organ or stem cell transplant	ICD-10	T86, Z94	1,2
Active cancer treatment	ICD-10	C00–C97 (except C44), D05.1, D39	1,2
Severe disorders of the immune system	ICD-10	D70.8, D80–D84, E31.00	2
Severe chronic renal disease	ICD-10	I12, I13, N00–N05, N07, N08, N11, N14, N18, N19, E10.2, E11.2, E14.2	1,2
Asthma requiring continuous medication	ICD-10	J45, J46	2, 3
	ICPC-2	R96	3
Severe chronic pulmonary disease	ICD-10	J41–J44, J47, Z90.2	2
Type 2 diabetes requiring medication	ICD-10	E11, E13, E14	2,3
	ICPC-2	T90	3
Blood glucose lowering drugs, excluding insulin	ATC	A10B	4
Down syndrome	ICD-10	Q90	2, 3
Predisposing to severe Covid-19			
Severe heart disease	ICD-10	I11–I13, I15, I20–I25, I50	1, 2
Neurological illness or condition that affects breathing	ICD-10	G70–G73, G80–G83, I60– I69	2
Immunosuppressive drug therapy for autoimmune disease			
Autoimmune disease	ICD-10	D86, K50, K51, L40, M02, M05–M07, M13.9, M45, M46.0, M46.1, M46.9, M94.1	1, 2
Immunosuppressive drug therapy	ATC	H02AB02, H02AB04, H02AB06, H02AB07, L01BA01, L01XC02, L04AA06, L04AA10, L04AA13, L04AA18, L04AA24, L04AA26, L04AA29, L04AA33, L04AA37, L04AB, L04AC, L04AD01, L04AD02, L04AX01, L04AX03	4
Severe chronic liver disease	ICD-10	K70.2, K70.3, K70.4, K71– K74	2
Type 1 diabetes	ICD-10	E10	2, 3
	ICPC-2	T89	3
Insulin and analogues	ATC	A10A	4
Adrenal insufficiency	ICD-10	E25.0, E27.1, E27.2, E27.4, E31.00, E31.01, E31.08, E89.6	1, 2
Sleep apnea	ICD-10	G47.3	2, 3
Continuous positive airway pressure therapy	NCSP	WX723, WX780	2
Psychotic disorders	ICD-10	F20–F29	2, 3
	ICPC-2	P72	3
Clozapine	ATC	N05AH02	4

ATC, Anatomical Therapeutic Chemical Classification System; ICD-10, International Statistical Classification of Diseases and Related Health Problems, tenth revision; ICPC-2, International Classification of Primary Care, second edition; NCSP, Nordic Nomesco Classification of Surgical Procedures.

Registers: 1, Special Reimbursement Register for Medicine Expenses; 2, Care Register for Health Care; 3, Register of Primary Health Care Visits; 4, Prescription Centre database.

Supplementary Table 2: Distribution of baseline characteristics and percentage vaccinated first with mRNA or adenovirus vector (AdV) vaccine, Finnish elderly aged 70+ years.

	Number of study subjects	Percentage vaccinated first with	
		mRNA vaccine	AdV vaccine
Age in years			
70-74	353956	79	10
75-79	231915	86	4
80-89	258389	89	1
90+	56832	83	1
Sex			
Male	384170	83	6
Female	516922	85	5
Presence of medical conditions predisposing to severe Covid-19			
No predisposing medical condition	376668	83	6
At least one highly predisposing medical condition	314949	85	5
At least one predisposing but no highly predisposing medical condition	209475	85	5
In Helsinki-Uusimaa hospital district			
No	685004	83	6
Yes	216088	87	2
In long-term care			
No	851206	84	5
Yes	49886	85	0

Supplementary Table 3: Distribution of baseline characteristics and percentage vaccinated first with mRNA or adenovirus vector (AdV) vaccine, chronically ill aged 16–69 years.

	Number of study subjects	Percentage vaccinated first with	
		mRNA vaccine	AdV vaccine
Age in years			
16-38	151887	33	4
39-51	151543	50	10
52-59	173280	58	19
60-64	138227	55	28
65-69	159589	32	54
Sex			
Male	403410	44	24
Female	371116	48	22
Presence of medical conditions predisposing to severe Covid-19			
At least one highly predisposing medical condition	329664	38	37
At least one predisposing but no highly predisposing medical condition	444862	51	12
In Helsinki-Uusimaa hospital district			
No	567944	46	22
Yes	206582	44	27

Supplementary Table 4: Crude and adjusted hazard ratios comparing the hazard of confirmed SARS-CoV-2 infection or Covid-19 hospitalization in study subjects who received exactly 1 or 2 doses of mRNA vaccine with the corresponding hazard in the unvaccinated, Finnish elderly aged 70+ years.

	SARS-CoV-2 infection						Covid-19 hospitalization					
	Crude hazard ratio			Adjusted hazard ratio			Crude hazard ratio			Adjusted hazard ratio		
	Est.	LCI	UCI	Est.	LCI	UCI	Est.	LCI	UCI	Est.	LCI	UCI
First dose												
0-6 DSV	0.773	0.624	0.956	0.669	0.541	0.827	0.465	0.270	0.801	0.425	0.246	0.733
7-13 DSV	0.846	0.684	1.046	0.707	0.572	0.875	0.644	0.400	1.038	0.577	0.357	0.931
14-20 DSV	0.766	0.607	0.966	0.618	0.490	0.780	0.831	0.538	1.285	0.734	0.473	1.138
21-27 DSV	0.745	0.581	0.956	0.589	0.459	0.755	0.498	0.286	0.869	0.433	0.248	0.758
28-34 DSV	0.693	0.527	0.911	0.534	0.406	0.701	0.470	0.263	0.841	0.414	0.231	0.742
35-41 DSV	0.735	0.554	0.976	0.545	0.411	0.722	0.411	0.218	0.774	0.360	0.191	0.680
42+ DSV	0.827	0.680	1.004	0.535	0.441	0.650	0.386	0.253	0.587	0.321	0.208	0.496
Second dose												
0-6 DSV	0.300	0.123	0.728	0.153	0.063	0.371	0.267	0.064	1.108	0.209	0.050	0.877
7+ DSV	0.725	0.530	0.990	0.250	0.181	0.347	0.087	0.021	0.355	0.072	0.017	0.300

DSV, day since vaccination; Est., Point estimate; LCI, lower 95% confidence interval limit; UCI, upper 95% confidence

interval limit

Supplementary Table 5: Crude and adjusted hazard ratios comparing the hazard of confirmed SARS-CoV-2 infection or Covid-19 hospitalization in study subjects who received exactly 1 or 2 doses of mRNA vaccine with the corresponding hazard in the unvaccinated, chronically ill aged 16–69 years.

	SARS-CoV-2 infection						Covid-19 hospitalization					
	Crude hazard ratio			Adjusted hazard ratio			Crude hazard ratio			Adjusted hazard ratio		
	Est.	LCI	UCI	Est.	LCI	UCI	Est.	LCI	UCI	Est.	LCI	UCI
First dose												
0-6 DSV	0.568	0.438	0.737	0.612	0.472	0.794	0.142	0.035	0.574	0.129	0.032	0.521
7-13 DSV	0.605	0.462	0.792	0.664	0.506	0.870	0.242	0.077	0.763	0.218	0.069	0.687
14-20 DSV	0.519	0.380	0.708	0.575	0.421	0.785	0.569	0.249	1.304	0.511	0.223	1.171
21-27 DSV	0.532	0.378	0.749	0.587	0.417	0.827	0.120	0.017	0.862	0.106	0.015	0.764
28-34 DSV	0.392	0.251	0.614	0.424	0.271	0.664	0.162	0.022	1.168	0.139	0.019	1.008
35-41 DSV	0.386	0.222	0.670	0.411	0.236	0.714	Not estimated			Not estimated		
42+ DSV	0.686	0.506	0.928	0.857	0.632	1.161	0.411	0.131	1.287	0.410	0.131	1.288
Second dose												
0-6 DSV	0.115	0.016	0.817	0.127	0.018	0.906	Not estimated			Not estimated		
7+ DSV	0.217	0.139	0.336	0.227	0.146	0.353	0.095	0.013	0.678	0.100	0.014	0.710

DSV, day since vaccination; Est., Point estimate; LCI, lower 95% confidence interval limit; UCI, upper 95% confidence

interval limit

Supplementary Table 6: Crude and adjusted hazard ratios comparing the hazard of confirmed SARS-CoV-2 infection or Covid-19 hospitalization in study subjects who received exactly 1 or 2 doses of adenovirus vector vaccine with the corresponding hazard in the unvaccinated, chronically ill aged 16–69 years.

	SARS-CoV-2 infection						Covid-19 hospitalization					
	Crude hazard ratio			Adjusted hazard ratio			Crude hazard ratio			Adjusted hazard ratio		
	Est.	LCI	UCI	Est.	LCI	UCI	Est.	LCI	UCI	Est.	LCI	UCI
First dose												
0-6 DSV	0.492	0.373	0.649	0.599	0.453	0.791	0.188	0.047	0.757	0.157	0.039	0.633
7-13 DSV	0.656	0.514	0.836	0.804	0.630	1.027	1.163	0.666	2.029	0.961	0.548	1.685
14-20 DSV	0.498	0.373	0.665	0.620	0.464	0.830	1.024	0.560	1.874	0.838	0.456	1.541
21-27 DSV	0.605	0.458	0.799	0.764	0.578	1.011	0.414	0.154	1.112	0.335	0.124	0.903
28-34 DSV	0.406	0.281	0.587	0.518	0.358	0.748	0.117	0.016	0.831	0.093	0.013	0.666
35-41 DSV	0.505	0.350	0.730	0.635	0.438	0.919	0.815	0.360	1.843	0.638	0.281	1.449
42+ DSV	0.401	0.318	0.507	0.497	0.393	0.630	0.564	0.327	0.973	0.423	0.243	0.736
Second dose												
0-6 DSV	0.687	0.220	2.147	1.375	0.439	4.309	Not estimated			Not estimated		
7+ DSV	Not estimated			Not estimated			Not estimated			Not estimated		

DSV, days since vaccination; Est., Point estimate; LCI, lower 95% confidence interval limit; UCI, upper 95% confidence

interval limit